bioAffinity Technologies Adds Director
Ticker: BIAFW · Form: 8-K · Filed: Oct 10, 2024 · CIK: 1712762
Sentiment: neutral
Topics: board-appointment, management-change, biotech
Related Tickers: BIAF
TL;DR
BIAF adds Dr. Zavala to board, boosting cancer research expertise.
AI Summary
On October 4, 2024, bioAffinity Technologies, Inc. announced the election of Dr. Maria Elena Zavala to its Board of Directors. Dr. Zavala brings extensive experience in molecular diagnostics and cancer research to the company. This appointment is part of the company's ongoing efforts to strengthen its leadership team as it advances its diagnostic technologies.
Why It Matters
The addition of a director with specialized expertise in molecular diagnostics and cancer research could bolster bioAffinity Technologies' strategic direction and product development in the competitive biotech sector.
Risk Assessment
Risk Level: medium — The appointment of a new director is a routine event, but the specific expertise of the director and the company's stage of development can influence the impact.
Key Players & Entities
- bioAffinity Technologies, Inc. (company) — Registrant
- Dr. Maria Elena Zavala (person) — Newly elected Director
- October 4, 2024 (date) — Date of earliest event reported
FAQ
Who was elected to the Board of Directors of bioAffinity Technologies, Inc.?
Dr. Maria Elena Zavala was elected to the Board of Directors.
What is Dr. Maria Elena Zavala's area of expertise?
Dr. Zavala has extensive experience in molecular diagnostics and cancer research.
When was the earliest event reported in this filing?
The earliest event reported was on October 4, 2024.
What is the Commission File Number for bioAffinity Technologies, Inc.?
The Commission File Number is 001-41463.
In which state was bioAffinity Technologies, Inc. incorporated?
bioAffinity Technologies, Inc. was incorporated in Delaware.
Filing Stats: 1,100 words · 4 min read · ~4 pages · Grade level 10.4 · Accepted 2024-10-10 09:23:43
Key Financial Figures
- $0.007 — ch registered Common Stock, par value $0.007 per share BIAF The Nasdaq Stock Mar
- $300,000 — s will receive an annual base salary of $300,000. The initial term of Mr. Edwards' emplo
- $50,000 — sh portion of the signing bonus will be $50,000 and the equity portion of the signing b
Filing Documents
- form8-k.htm (8-K) — 51KB
- ex10-1.htm (EX-10.1) — 119KB
- ex99-1.htm (EX-99.1) — 16KB
- ex99-1_001.jpg (GRAPHIC) — 19KB
- 0001493152-24-040679.txt ( ) — 456KB
- biaf-20241004.xsd (EX-101.SCH) — 4KB
- biaf-20241004_def.xml (EX-101.DEF) — 29KB
- biaf-20241004_lab.xml (EX-101.LAB) — 36KB
- biaf-20241004_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 10, 2024 BIOAFFINITY TECHNOLOGIES, INC. (Registrant) By: /s/ Maria Zannes Name: Maria Zannes Title: President and Chief Executive Officer